Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Survival of patients with recurrent glioblastoma multiforme treated with local carmustine wafer (Gliadel) in relation to the methylation of methylguanin-DNA-methyltransferase (MGMT) promotor

Next Previous
Trial Profile

Survival of patients with recurrent glioblastoma multiforme treated with local carmustine wafer (Gliadel) in relation to the methylation of methylguanin-DNA-methyltransferase (MGMT) promotor

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 03 Jan 2022 Status changed from active, no longer recruiting to completed.
  • 01 Jan 2021 Status changed from recruiting to active, no longer recruiting.
  • 01 Apr 2020 Planned End Date changed from 30 Sep 2018 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top